Comparative Pharmacology
Head-to-head clinical analysis: CORZIDE versus TECZEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORZIDE versus TECZEM.
CORZIDE vs TECZEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.
Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.
1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.
None Documented
None Documented
Nadolol: 14-24 hours (prolonged in renal impairment up to 45 hours); bendroflumethiazide: 8-9 hours (may be prolonged in renal dysfunction).
Terminal elimination half-life: 3-4 hours for diltiazem; clinical context: requires twice-daily dosing due to short half-life.
Nadolol: ~73% excreted unchanged in urine via glomerular filtration; bendroflumethiazide: ~30% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal: 40-50% unchanged; hepatic/biliary/fecal: 50-60% as metabolites.
Category C
Category C
Antihypertensive combination
Antihypertensive combination